drugset
drugset / Trial / NCT04669899

Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors

NCT04669899 ↗

Phase 1/2 Completed 190 enrolled Jounce Therapeutics, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

JTX-8064-101 is a Phase 1/2, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose (RP2D) of JTX-8064 alone and in combination with a PD-1 inhibitor (PD-1i).

Timeline

Start
2021-01-12
Primary completion
2023-11-28
Completion
2023-11-28

Drugs

EvaluationDrugModalityDoseRoute
Subject POLZASTOBART Monoclonal antibody — —
Subject Pimivalimab Monoclonal antibody — —

Indications

cancer